<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02885662</url>
  </required_header>
  <id_info>
    <org_study_id>CS3150-A-J307</org_study_id>
    <nct_id>NCT02885662</nct_id>
  </id_info>
  <brief_title>Study of CS-3150 in Patients With Primary Aldosteronism</brief_title>
  <official_title>A Study of CS-3150 to Evaluate Efficacy and Safety in Patients With Primary Aldosteronism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine antihypertensive effect and safety of CS-3150 in patients with primary
      aldosteronism.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">July 20, 2017</completion_date>
  <primary_completion_date type="Actual">July 20, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in sitting blood pressure</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
    <description>Change from baseline in sitting systolic and diastolic blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time course of sitting blood pressure</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
    <description>Time course of sitting systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving sitting blood pressure goal</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Primary Aldosteronism</condition>
  <arm_group>
    <arm_group_label>CS-3150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CS-3150 2.5 to 5.0 mg , orally, once daily after breakfast for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS-3150</intervention_name>
    <description>CS-3150 2.5 to 5.0 mg , orally.</description>
    <arm_group_label>CS-3150</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects aged 20 years or older at informed consent

          -  Patients diagnosed primary aldosteronism by screening test of plasma aldosterone
             concentration (PAC) and aldosterone to renin ratio (ARR), and confirmatory testing

          -  Patients satisfying following blood pressure;

               -  sitting systolic blood pressure (SBP) ≥ 140 mmHg and &lt;180 mmHg

               -  sitting diastolic blood pressure (DBP) ≥ 90 mmHg and &lt;110 mmHg

        Exclusion Criteria:

          -  Secondary hypertension except primary aldosteronism or hypertensive emergency

          -  Patients diagnosed diabetic nephropathy

          -  Patients with type 1 diabetes

          -  Estimated glomerular filtration rate (eGFR) &lt; 30 mL/min/1.73m2

          -  Serum potassium level &lt; 3.0 or ≥ 5.1 milliequivalent (mEq)/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Japan Organaization of Occupational Health and Safety(JOHAS), Yokohama Rosai Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>222-0036</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2016</study_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary aldosteronism</keyword>
  <keyword>Hypertension</keyword>
  <keyword>mineralocorticoid receptor antagonist</keyword>
  <keyword>Developmental Phase III</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperaldosteronism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

